Novartis Records $1.9 Billion Charge After Trial Failure
The pharmaceutical giant faces a major financial impairment following the unsuccessful phase 3 trial of its drug del-desiran.
Updated on Oct. 27, 2026 in Healthcare
Live Poll
Should large pharmaceutical companies focus on smaller acquisitions to mitigate risks after clinical trial failures?
In September 2026, Novartis recorded a $1.9 billion impairment charge following the failure of its del-desiran drug to meet primary endpoints in a phase 3 clinical trial for myotonic dystrophy type 1. The company intends to use these funds to cover the costs of conducting an additional pivotal study for the drug.
Why it matters
The significant impairment charge highlights the financial risks inherent in late-stage drug development despite the company's aggressive M&A strategy. Novartis continues to balance these setbacks against its broader portfolio, including other ongoing pipeline programs.
Novartis recorded a $1.9 billion impairment charge in Q3 2026 related to the del-desiran program. This follows the company's 2025 acquisition of Avidity Biosciences, which was valued at $12 billion.
The players
Novartis
This is a Switzerland-based multinational pharmaceutical corporation that develops and manufactures a wide range of healthcare and medical products.
Vas Narasimhan
He serves as the Chief Executive Officer of Novartis and is responsible for steering the firm's strategic focus and growth outlook.
The details
Novartis is navigating multiple clinical hurdles, including a pause on its rapcabtagene autoleucel program following three patient deaths due to immune effector cell-associated hemophagocytic syndrome. While the firm maintains its growth outlook, the program remains on clinical hold in the U.S. and Europe.
Timeline
2025-10: Novartis completed the $12 billion acquisition of Avidity Biosciences.
Summer 2026: Novartis paused development of rapcabtagene autoleucel.
September 2026: The phase 3 clinical trial for del-desiran failed.
Q3 2026: Novartis recorded a $1.9 billion impairment charge.
Market Landscape
The impairment charge represents a notable financial adjustment following the 2025 Novartis acquisition of Avidity Biosciences. This event tests the company's resilience as it continues to execute a $2 billion threshold for bolt-on M&A activity while managing its internal drug pipeline.
Investors and stakeholders may see shifts in corporate resource allocation as the company accounts for the $1.9 billion charge. Future product availability for patients remains dependent on the results of the additional pivotal study and the resolution of the rapcabtagene program hold.
The takeaway
Large pharmaceutical firms must balance high-stakes clinical research with the financial volatility that follows unexpected trial failures. Maintaining a diversified portfolio of treatments is essential for managing the long-term impact of individual program setbacks.
What happens next
Novartis plans to provide updates regarding the clinical hold on the rapcabtagene autoleucel program in the coming months.
Further reading
For more on industry developments, visit the Healthcare section.
Live Poll
Should large pharmaceutical companies focus on smaller acquisitions to mitigate risks after clinical trial failures?
